Nana-Bilkisu Habib experienced intense pain and hospitalization after a mix-up with her sickle cell medication, Oxbryta, which was later recalled by Pfizer. Doctors and patients are grappling with the decision to taper patients off the drug to avoid potential risks. The withdrawal of Oxbryta has left many sickle cell patients uncertain about their treatment options, as alternative treatments have drawbacks and limited accessibility. The lack of data and guidance in handling the withdrawal of Oxbryta has exacerbated concerns among the sickle cell community, who have historically faced neglect and discrimination in healthcare. The sudden recall of Oxbryta has left patients and doctors in a difficult position, navigating the risks and uncertainties of managing sickle cell disease without a crucial medication.
Source link
Sickle cell community scrambles after a Pfizer drug is pulled from the market
